William Looney
William Looney
Editor-in-Chief
wlooney@advanstar.com
William Looney is the Editor in Chief of Pharmaceutical Executive magazine, a monthly print and weekly on-line publication focused on the “c suite” concerns of senior managers in the biopharmaceutical industry. In addition to editorial content, he is responsible for supporting the magazine through related educational media activities and serving as a thought leader in contacts between the magazine and a wide variety of organizations.
Prior to joining Pharmaceutical Executive in August 2009, Mr. Looney served for 11 years as Senior Director at Pfizer, Inc. where he managed the company’s public policy issue development, positioning and advocacy activities outside the US. In that capacity, he worked closely with the academic and think tank community, coordinated Pfizer CEO relationships with the World Economic Forum, Japan’s Nikkei Management Forum and other policy groups, and chaired committees of key biopharma trade associations, including PhRMA and the IFPMA.
Earlier in his career, he served as an internal communications manager and speech writer at Warner Lambert Company in both the US and in Europe. He also was senior editor for the Economist Intelligent Unit, where he was responsible for consumer issues and management practices in Europe.
He has also been a consultant to the organization for Economic Cooperation and Development [OECD], and is the author of numerous research papers and studies focused on the relationships between product and process innovation and public health.
In March 2011 he was honored by American Business Media with a Neal Award for 'Best Commentary' for his monthly 'From the Editor' columns.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
